Archives
-
MG-132 (Z-LLL-al) for Proteasome Assays
2026-09-21
MG-132 (Z-LLL-al) provides a cell-permeable way to interrogate proteasome-dependent protein turnover, apoptosis, ROS signaling, and cell-cycle control. This guide translates a hypoxic cardiomyocyte study into practical assay designs while emphasizing dosing, controls, stability, and interpretation limits.
-
Z-IETD-FMK: Mapping Caspase-8 in Immunity
2026-09-20
A translational perspective on using Z-IETD-FMK to dissect caspase-8-dependent apoptosis, T cell activation, NF-κB signaling, and death-receptor biology across infection and cancer research.
-
KX2-391 Dihydrochloride in SRC-Driven CRC
2026-09-19
KX2-391 dihydrochloride offers a mechanistically resolved way to study SRC-dependent colorectal cancer metastasis, while also supporting HBV and BoNT/A research. This article translates pathway biology into assay-selection and interpretation strategies rather than repeating a conventional compound protocol.
-
Adefovir (GS-0393) HBV Research Workflow
2026-09-18
Adefovir (GS-0393) combines a defined HBV DNA polymerase mechanism with a second use as an OAT1 transporter probe. This workflow shows how to prepare, dose, validate, and troubleshoot the compound while adapting structural-biology lessons from a DDX3 crystallization study without overstating cross-domain evidence.
-
Entecavir (BMS200475): A Translational HBV Strategy
2026-09-18
Entecavir, also known as BMS200475, offers a mechanistically focused framework for chronic hepatitis B research. This thought-leadership article connects HBV polymerase inhibition with assay design, resistance modeling, safety monitoring, clinical translation, and the disciplined interpretation of antiviral evidence.
-
KX2-391 Dihydrochloride: Assay Logic
2026-09-17
KX2-391 dihydrochloride, also called Tirbanibulin dihydrochloride, is best understood through mechanism-resolved assay design rather than a single potency value. This guide connects Src, tubulin, HBV transcription, and BoNT/A readouts to practical experimental decisions.
-
Why Cas9 mRNA Precision Starts with RNA Control
2026-09-17
A mechanistic and translational analysis of how Cap1 capping, m1Ψ modification, poly(A) tailing, and nuclear export control can shape CRISPR-Cas9 performance, with practical guidance for evaluating EZ Cap™ Cas9 mRNA (m1Ψ) in mammalian genome-editing workflows.
-
Azilsartan: A Causal Map for RAS Assays
2026-09-16
Azilsartan (TAK-536) is more than a potent AT1 receptor tool: it can help researchers distinguish receptor-dependent signaling from broader microglia-conditioned effects. This article translates a reactive astrocyte study into a practical framework for assay design, interpretation, and cross-domain validation.
-
L. reuteri FN041 Remodels the Colitis Gut Ecosystem
2026-09-16
This Food Bioscience study shows that human milk-derived Limosilactobacillus reuteri FN041 alleviated DSS-induced colitis in mice while improving barrier-related, inflammatory, microbiome, and metabolomic readouts. Its main contribution is an integrated view of probiotic activity, linking clinical and histological improvement with coordinated changes in gut bacteria and cecal metabolites rather than treating microbiota remodeling as an isolated endpoint.
-
Carbon-Ion Radiotherapy, Ferroptosis, and DHODH
2026-09-15
Wang and Cai report that carbon-ion radiotherapy suppresses DHODH, increases ferroptosis-associated stress in gastric cancer cells, and promotes an M1-like macrophage phenotype through tumor-conditioned medium. The study connects radiation response with tumor-cell redox biology and macrophage polarization, while identifying DHODH as a potential mechanistic modifier rather than establishing a clinically ready treatment strategy.
-
KX2-391 Dihydrochloride in CRC Metastasis Assays
2026-09-15
KX2-391 dihydrochloride offers a mechanistically informed way to interrogate SRC-dependent colorectal cancer metastasis. This guide translates the FGF19–ELF4–FGFR4–SRC findings into assay design decisions while defining the compound’s cross-domain research boundaries.
-
Protease Inhibitor Cocktail for Plant Signal Fidelity
2026-09-14
Discover how a Protease Inhibitor Cocktail preserves the molecular evidence behind NSP2–MYB40 research, from plant cell protein stability to interaction assays. This guide presents an assay-centered strategy for reducing protein degradation without obscuring biologically meaningful results.
-
Liraglutide and the Brain–Kidney AVP Axis
2026-09-14
Greenwood and colleagues combine a human before-and-after study with rat pituitary proteomics, phosphoproteomics, functional AVP reporter experiments, and renal signaling analysis to explain how liraglutide may alter fluid homeostasis. The study links reduced circulating arginine vasopressin to sex- and time-dependent synaptic regulation and downstream aquaporin 2 changes, while highlighting the need to separate reporter activity from direct molecular abundance.
-
Applied 4-Ethylphenyl Sulfate Workflows
2026-09-13
Build reproducible renal biomarker, gut microbiota-brain interaction, and adsorption assays with 4-ethylphenyl sulfate. This guide connects compound handling to matrix-aware quantitation, behavioral model design, and practical troubleshooting.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-12
A 2026 FASEB Journal study developed chemically modified p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, inhibited cell-cycle progression and tumor growth, and achieved bladder-localized expression with limited transient systemic distribution in mice.